Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains

Vaccine

Volumn 27, Issue 39, 2009, Pages 5320-5325

  Malerczyk, Claudius ^a   Selhorst, Thomas ^b   Tordo, Noël ^c   Moore, Susan ^d   Müller, Thomas ^b  

^a GSK Marburg Vaccines and Diagnostics   (Germany)

^b FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^c INSTITUT PASTEUR   (France)

^d KANSAS STATE UNIVERSITY   (United States)

Author keywords

ABLV; EBLV; Lyssavirus; PCECV; Rabies; RFFIT

Indexed keywords

NEUTRALIZING ANTIBODY; RABIES VACCINE;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CROSS REACTION; HUMAN; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; RABIES VIRUS; VACCINATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; CHICK EMBRYO; CROSS REACTIONS; HUMANS; LYSSAVIRUS; MIDDLE AGED; NEUTRALIZATION TESTS; RABIES; RABIES VACCINES; YOUNG ADULT;

EID: 68349090309     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.095     Document Type: Article

References (47)

1. Schneider L.G., and Cox J.H. Bat lyssaviruses in Europe. Curr Top Microbiol Immunol 187 (1994) 207-218
2. Badrane H., Bahloul C., Perrin P., and Tordo N. Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 75 7 (2001) 3268-3276
3. Tordo N., Benmansour A., Calisher C., Dietzgen R.G., Fang R.-X., Jackson A.O., et al. Rhabdoviridae. In: Fauquet C.M., Mayo M.A., Maniloff J., Desselberger U., and Ball L.A. (Eds). Virus taxonomy, VIIIth report of the ICTV (2004), Elsevier/Academic Press, London 623-644
4. Hanna J.N., Carney I.K., Smith G.A., Tannenberg A.E., Deverill J.E., Botha J.A., et al. Australian bat lyssavirus infection: a second human case, with a long incubation period. Med J Aust 172 12 (2000) 597-599
5. Allworth A., Murray K., and Morgan J. A human case of encephalitis due to a lyssavirus, recently identified in fruit bats. Communicable Diseases Intelligence (Commun Dis Intell) 20 24 (1996) 504
6. Gould A.R., Hyatt A.D., Lunt R., Kattenbelt J.A., Hengstberger S., and Blacksell S.D. Characterisation of a novel lyssavirus isolated from pteropid bats in Australia. Virus Res 54 2 (1998) 165-187
7. Kuzmin I.V., Hughes G.J., Botvinkin A.D., Orciari L.A., and Rupprecht C.E. Phylogenetic relationships of Irkut and West Caucasian bat viruses within the Lyssavirus genus and suggested quantitative criteria based on the N gene sequence for lyssavirus genotype definition. Virus Res 111 1 (2005) 28-43
8. Markotter W., Kuzmin I., Rupprecht C.E., Randles J., Sabeta C.T., Wandeler A.I., et al. Isolation of Lagos Bat Virus from water mongoose. Emerg Infect Dis 12 12 (2006) 1913-1918
9. Smith J.S., Messenger S., Davids A., Yager P., and Rupprecht C.E. Bat rabies: spillover infection and reservoir establishment. 12th international meeting on advances in rabies research and control in the Americas. Peterborough, Canada, November 12-16 (2001) 46
10. Dacheux L., Larrous F., Mailles A., Boisseleau D., Delmas O., Biron C., et al. European bat lyssavirus transmission among cats, Europe. Emerg Infect Dis 15 2 (2009) 280-284
11. Badrane H., and Tordo N. Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. J Virol 75 17 (2001) 8096-8104
12. Fooks A.R., Brookes S.M., Johnson N., McElhinney L.M., and Hutson A.M. European bat lyssaviruses: an emerging zoonosis. Epidemiol Infect 131 3 (2003) 1029-1039
13. Roine R.O., Hillbom M., Valle M., Haltia M., Ketonen L., Neuvonen E., et al. Fatal encephalitis caused by a bat-borne rabies-related virus. Clinical findings. Brain 111 (1988) 1505-1516
14. Selimov M.A., Tatarov A.G., Botvinkin A.D., Klueva E.V., Kulikova L.G., and Khismatullina N.A. Rabies-related Yuli virus; identification with a panel of monoclonal antibodies. Acta Virol 33 6 (1989) 542-546
15. Fooks A.R., McElhinney L.M., Pounder D.J., Finnegan C.J., Mansfield K., Johnson N., et al. Case report: isolation of a European bat lyssavirus type 2a from a fatal human case of rabies encephalitis. J Med Virol 71 2 (2003) 281-289
16. Botvinkin A.D., Selnikova O.P., Antonova L.A., Moiseeva A.B., and Nesterenko E.Y. Human rabies case caused from a bat bite in Ukraine. Rabies Bulletin Europe 29 3 (2005) 5-7
17. Fooks A.R., Marston D., Parsons G., Earl D., Dicker A., and Brookes S.M. Isolation of EBLV-2 in a Daubenton's bat (Myotis daubentonii) found in Oxfordshire. Vet Rec 159 16 (2006) 534-535
18. Freuling C., Grossmann E., Conraths F.J., Schameitat A., Kliemt J., Auer E., et al. First isolation of EBLV-2 in Germany. Vet Microbiol 131 1-2 (2008) 26-34
19. Müller T., Johnson N., Freuling C.M., Fooks A.R., Selhorst T., and Vos A. Epidemiology of bat rabies in Germany. Arch Virol 152 (2007) 273-288
20. Rabies Bulletin Europe; available at: http://www.who-rabies-bulletin.org; assessed 01/February/2008.
21. Müller T., Selhorst T., Burow J., Schameitat A., and Vos A. Cross reactive antigenicity in orally vaccinated foxes and raccoon dogs against European bat lyssavirus type 1 and 2. Dev Biol (Basel) (2006) 195-204
22. Scheiermann N., Baer J., Hilfenhaus J., Marcus I., and Zoulek G. Reactogenicity and immunogenicity of the newly developed purified chick embryo cell (PCEC)-rabies vaccine in man. Zentralbl Bakteriol Mikrobiol Hyg [A] 265 3-4 (1987) 439-450
23. Vodopija I., Sureau P., Lafon M., Baklaic Z., Ljubicić M., Svjetlicić M., et al. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule. Vaccine 4 4 (1986) 245-248
24. Briggs D.J., Banzhoff A., Nicolay U., Sirikwin S., Dumavibhat B., Tongswas S., et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 78 5 (2000) 693-698
25. Nicholson K.G., Farrow P.R., Bijok U., and Barth R. Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man. Vaccine 5 3 (1987) 208-210
26. Kamoltham T., Thinyounyong W., Phongchamnaphai P., Phraisuwan P., Khawplod P., Banzhoff A., et al. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. J Pediatr 151 2 (2007) 173-177
27. Malerczyk C., Briggs D.J., Dreesen D.W., and Banzhoff A. Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine. J Travel Med 14 1 (2007) 63-64
28. Ljubicic M., Vodopija I., Smerdel S., Baklaic Z., Svjetlicic M., and Lojkic M. Efficacy of PCEC vaccine in post-exposure rabies prophylaxis. In: Vodopija I., Nicholson K.G., Smerdel S., and Bijok U. (Eds). Improvements in rabies post-exposure treatment (1985), Zagreb Institute of Public Health and Institute of Immunology, Zagreb 181-186
29. Quiambao B.P., Dimaano E.M., Ambas C., Davis R., Banzhoff A., and Malerczyk C. Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine 23 14 (2005) 1709-1714
30. Dietzschold B., and Hooper D.C. Human diploid cell culture rabies vaccine (HDCV) and purified chick embryo cell culture rabies vaccine (PCECV) both confer protective immunity against infection with the silver-haired bat rabies virus strain (SHBRV). Vaccine 16 17 (1998) 1656-1659
31. Hanlon C.A., Kuzmin I.V., Blanton J.D., Weldon W.C., Manangan J.S., and Rupprecht C.E. Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res 111 1 (2005) 44-54
32. Lafon M., Herzog M., and Sureau P. Human rabies vaccines induce neutralising antibodies against the European bat rabies virus (Duvenhage). Lancet 2 8505 (1986) 515
33. Lafon M., Bourhy H., and Sureau P. Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice. Vaccine 6 4 (1988) 362-368
34. Jallet C., Jacob Y., Bahloul C., Drings A., Desmezières E., Tordo N., et al. Chimeric lyssavirus glycoproteins with increased immunological potential. J Virol 73 (1999) 225-233
35. Brookes S.M., Healy D.M., and Fooks A.R. Ability of rabies vaccine strains to elicit cross-neutralising antibodies. Dev Biol (Basel) 125 (2006) 185-193
36. Knobel D.L., Cleaveland S., Coleman P.G., Fèvre E.M., Meltzer M.I., Miranda M.E.G., et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83 5 (2005) 360-368
37. Brookes S.M., Parsons G., Johnson N., McElhinney L.M., and Fooks A.R. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 23 32 (2005) 4101-4109
38. Wright E., Temperton N.J., Marston D.A., McElhinney L.M., Fooks A.R., and Weiss R.A. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J Gen Virol 89 (2008) 2204-2213
39. Smith J.S., Yager P.A., and Baer G.M. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody. In: Meslin F.X., Kaplan M.M., and Koprowski H. (Eds). Laboratory techniques in rabies (1996), WHO, Geneva, Switzerland 181-191
40. McColl K.A., Chamberlain T., Lunt R.A., Newberry K.M., and Westbury H.A. Susceptibility of domestic dogs and cats to Australian bat lyssavirus (ABLV). Vet Microbiol 123 1-3 (2007) 15-25
41. Bahloul C., Jacob Y., Tordo N., and Perrin P. DNA-based immunisation for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine 16 (1998) 417-425
42. Tordo N., Bourhy H., Sather S., and Ollo R. Structure and expression in baculovirus of the Mokola virus glycoprotein: an efficient recombinant vaccine. Virology 194 1 (1993) 59-65
43. Weyer J., Kuzmin I.V., Rupprecht C.E., and Nel L.H. Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes. Epidemiol Infect (2007) 1-9
44. Hanlon C.A., DeMattos C.A., DeMattos C.C., Niezgoda M., Hooper D.C., Koprowski H., et al. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 19 28-29 (2001) 3834-3842
45. Schumacher C.L., Dietzschold B., Ertl H.C., Niu H.S., Rupprecht C.E., and Koprowski H. Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. J Clin Invest 84 3 (1989) 971-975
46. Blancou J., Baltazar R.S., Molli I., and Stoltz J.F. Effective postexposure treatment of rabies-infected sheep with rabies immune globulin and vaccine. Vaccine 9 6 (1991) 432-437
47. Morris J., Crowcroft N.S., Fooks A.R., Brookes S.M., and Andrews N. Rabies antibody levels in bat handlers in the United Kingdom: immune response before and after purified chick embryo cell rabies booster vaccination. Hum Vaccin 3 5 (2007) 165-170